Strategic Investment Advisors MI Takes $853,000 Position in Merck & Co., Inc. $MRK

Strategic Investment Advisors MI bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 7,088 shares of the company’s stock, valued at approximately $853,000.

Several other large investors have also recently added to or reduced their stakes in the business. Ashton Thomas Securities LLC grew its holdings in Merck & Co., Inc. by 17.7% in the first quarter. Ashton Thomas Securities LLC now owns 8,271 shares of the company’s stock valued at $995,000 after purchasing an additional 1,242 shares during the period. Strategic Planning Inc. purchased a new position in Merck & Co., Inc. during the first quarter worth approximately $209,000. Arete Wealth Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 30.8% in the 1st quarter. Arete Wealth Advisors LLC now owns 51,371 shares of the company’s stock valued at $6,179,000 after purchasing an additional 12,096 shares during the last quarter. Opal Capital LLC boosted its holdings in shares of Merck & Co., Inc. by 321.5% in the 1st quarter. Opal Capital LLC now owns 11,928 shares of the company’s stock valued at $1,435,000 after purchasing an additional 9,098 shares during the last quarter. Finally, Guardian Partners Inc. grew its stake in shares of Merck & Co., Inc. by 2.5% during the 1st quarter. Guardian Partners Inc. now owns 12,884 shares of the company’s stock valued at $1,554,000 after buying an additional 310 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on MRK. UBS Group upped their price objective on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. CICC Research started coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Cantor Fitzgerald reissued a “neutral” rating and set a $120.00 price target on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Bank of America upped their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Finally, Wells Fargo & Company raised their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 8th. Thirteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.50.

Merck & Co., Inc. Trading Down 0.3%

MRK opened at $129.95 on Friday. The firm has a market capitalization of $320.96 billion, a P/E ratio of 36.61, a P/E/G ratio of 5.17 and a beta of 0.19. The firm’s 50 day moving average is $123.02 and its 200-day moving average is $118.37. Merck & Co., Inc. has a 52-week low of $77.53 and a 52-week high of $135.05. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.22 earnings per share. Analysts expect that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. Merck & Co., Inc.’s payout ratio is currently 95.77%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Barclays raised its price target on Merck from $140 to $150 and maintained an “overweight” rating, implying meaningful potential upside from recent trading levels. Barclays raises Merck price target
• Positive Sentiment: Erste Group modestly increased its fiscal 2027 EPS forecast to $9.54 from $9.52, signaling slightly stronger expectations for Merck’s longer-term earnings power. Erste Group raises Merck EPS estimate
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend supports the stock’s income appeal and represents an annualized yield of approximately 2.7%. Merck announces fourth-quarter dividend
• Positive Sentiment: A Merck-Wellcome joint venture is preparing doses of an experimental Ebola vaccine for clinical trials, providing a potential public-health and pipeline opportunity, although it is not an immediate earnings driver. Merck and Wellcome Ebola vaccine partnership
• Neutral Sentiment: Analysts expect second-quarter revenue of about $16.33 billion and a loss of $0.26 per share, with acquisition-related costs, Keytruda performance, and Gardasil demand likely to determine whether results beat or miss expectations. Merck second-quarter earnings preview
• Neutral Sentiment: Valuation analysis finds Merck attractive on discounted cash flow and cash-flow measures but more fairly valued based on earnings, suggesting further gains will require continued fundamental execution. Merck valuation analysis
• Negative Sentiment: Near-term uncertainty ahead of earnings—including acquisition costs and ongoing Gardasil challenges—may be weighing on sentiment despite expected strength from Keytruda. Merck earnings metrics preview

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.